BioGaia AB: Interim Management Statement January – June 2023
SECOND QUARTER 2023 Figures in parentheses refer to the corresponding period last year, unless otherwise specified. · Net sales amounted to SEK 315.2 million (288.1), an increase of SEK 27.1 million, or 9% (excluding foreign exchange effects, 2%). · Net sales in the Paediatrics segment amounted to SEK 231.7 million (232.7), a change of 0% (excluding foreign exchange effects a decrease of 7%). · Net sales in the Adult Health segment amounted to SEK 83.0 million (54.2), an increase of 53% (excluding foreign exchange effects, an increase of 43%). · Operating expenses amounted